Clinical trial · no report yet · Phase 3

EA5181 trial (durvalumab): what clinicians have said so far

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT04092283 ↗
Active, not recruiting
National Cancer Institute (NCI)
Deep size, estimated: 301+ verified statements

We haven't built an HCP commentary report on EA5181 (durvalumab in unresectable stage III non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on EA5181 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
57 posts on X
3 YouTube videos
1 podcast episode

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Phase: Phase 3
Status: Active, not recruiting
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma
Interventions: Carboplatin; Cisplatin; Durvalumab; Etoposide; Paclitaxel; Pemetrexed Disodium
Arms: Arm A (durvalumab, chemotherapy, durvalumab) · Experimental
Arm B (chemotherapy, durvalumab) · Active comparator
Enrollment: 660 (estimated)
Primary outcomes: Overall survival (OS)
Sponsor: National Cancer Institute (NCI)
Start: Apr 29, 2020
Primary completion: Dec 31, 2028 (estimated)
Results posted: No
Registry record: NCT04092283 · updated Oct 26, 2026

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on EA5181 so far

Reports on the same drug or indication

The trial